The ZBTB7A mutation may collaborate with the RUNX1-RUNX1T1 fusion gene in two ways and could be a new target to treat acute myeloid leukemia (AML) (Figure 1). This evidence concerns the gene ZBTB7A and acute myeloid leukemia.